Lonza acquires Arabinogalactan business assets from Larex Inc.

Lonza acquires Arabinogalactan business assets from Larex Inc. Lonza Group announces the acquisition of assets which comprise Larex, Inc.’s Larch Arabinogalactan business, including intellectual property, proprietary processing technology, manufacturing operations in Cohasset, Minnesota (USA), certain inventory and customer lists.
Home Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label Supplement Group Targets Consumer Education ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway FDA Presents Compliance Guide for Structure/Function Claims New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava Modern Science Confirms Ancient Wisdom! Modern Science Confirms Ancient Wisdom! "Natural" or "Plant-Derived" Labeling Can Mislead CDN: Natural Health Products Report - Update NPI Editorial: Are we using Best Practices? AHPA Update: Kava Information from the AHPA Executive Committee European Commission Proposes Registration Scheme for Herbal Medicine to Avoid Need for Testing Statement on Kava in New Zealand BICL Discontinues Kava Sales; Health Canada Issues Consumer Warning BICL Discontinues Kava Sales; Health Canada Issues Consumer Warning Enzymotec Granted New US Patent on Lyso-phospholipids Company has announced that it has received US-approval for its proprietary enzymatic technology for producing Lyso-phospholipids. Natural Health Trends Corp. Announces Fourth Quarter and Twelve Months 2005 Results Company reports Q4 sales of $43.7 million, up 20% from the $36.3 million for the comparable period a year ago, with a net loss of $6.3 million, or $0.88 per fully diluted share, compared to a net loss of $0.8 million or $0.12 per fully diluted share a year ago. Natural Health Trends Corp. Announces Fourth Quarter and Twelve Months 2005 Results Company reports Q4 sales of $43.7 million, up 20% from the $36.3 million for the comparable period a year ago, with a net loss of $6.3 million, or $0.88 per fully diluted share, compared to a net loss of $0.8 million or $0.12 per fully diluted share a year ago. Hansen Natural Reports Record First Quarter Sales And Profits Company reports gross sales of $137.8 million compared to $73.0 million a year earlier, with net income of $21.1 million, or $0.84 per diluted share, compared $8.8 million or $0.37 per diluted share for the same quarter last year. Hansen Natural Reports Record First Quarter Sales And Profits Company reports gross sales of $137.8 million compared to $73.0 million a year earlier, with net income of $21.1 million, or $0.84 per diluted share, compared $8.8 million or $0.37 per diluted share for the same quarter last year. Omega Protein Reports 2006 First Quarter Results Company reports net income of of $2.5 million (10 cents per share), compared with net income of $107,000, or 0 cents a share, for the first quarter of the previous year, on revenues of $28.3 million this year, versus revenues of $23.8 million for the 2005 comparable quarter. Omega Protein Reports 2006 First Quarter Results Company reports net income of of $2.5 million (10 cents per share), compared with net income of $107,000, or 0 cents a share, for the first quarter of the previous year, on revenues of $28.3 million this year, versus revenues of $23.8 million for the 2005 comparable quarter. Advitech Announces Its First-Quarter Highlights And Financial Results Company reports quarterly net loss of $361,872 or $0.01 per share, compared to a net loss of $671,269 or $0.01 per share for the same period in 2005, with cash and cash equivalents totalling $730,229, compared to $686,742 as at December 31, 2005. Advitech Announces Its First-Quarter Highlights And Financial Results Company reports quarterly net loss of $361,872 or $0.01 per share, compared to a net loss of $671,269 or $0.01 per share for the same period in 2005, with cash and cash equivalents totalling $730,229, compared to $686,742 as at December 31, 2005. MGP Ingredients Announces Fiscal 2006 Third Quarter Results Company reports net income of $2,083,000, or $0.13 in basic earnings per share compared with net income of $1,627,000, or $0.10 per share, for the third quarter of fiscal 2005, on net sales of $79,422,000 versus net sales of $71,186,000 in the prior year period. MGP Ingredients Announces Fiscal 2006 Third Quarter Results Company reports net income of $2,083,000, or $0.13 in basic earnings per share compared with net income of $1,627,000, or $0.10 per share, for the third quarter of fiscal 2005, on net sales of $79,422,000 versus net sales of $71,186,000 in the prior year period. Mannatech Reports First Quarter Results Company reports sales of $99.0 million, compared to $85.1 million prior year, with net income of $5.9 million from $4.7 million last year. Mannatech Reports First Quarter Results Company reports sales of $99.0 million, compared to $85.1 million prior year, with net income of $5.9 million from $4.7 million last year. Cognis acquires Norwegian manufacturer of high-quality omega-3 fish oils Cognis announces that it will acquire Napro Pharma AS, a Norwegian manufacturer of high-quality omega-3 fish oils for the nutrition industry. The Napro Pharma product portfolio further strengthens Cognis’ Nutrition & Health Strategic Business Unit as a leading supplier of natural-source ingredients sold worldwide for the dietary supplement and functional food markets. The transaction is expected to be completed by end of June, 2006. Cognis acquires Norwegian manufacturer of high-quality omega-3 fish oils Cognis announces that it will acquire Napro Pharma AS, a Norwegian manufacturer of high-quality omega-3 fish oils for the nutrition industry. The Napro Pharma product portfolio further strengthens Cognis’ Nutrition & Health Strategic Business Unit as a leading supplier of natural-source ingredients sold worldwide for the dietary supplement and functional food markets. The transaction is expected to be completed by end of June, 2006. Lifeline Therapeutics, Inc. Announces Q3 FY 2006 Financial and Operating Results Company reports revenues of $1,390,623 and a loss of $(670,911), or $(0.03) per share, for its third fiscal quarter, compared to $25,819, resulting in a loss of $(1,519,829), or $(0.09) per share prior year. Lifeline Therapeutics, Inc. Announces Q3 FY 2006 Financial and Operating Results Company reports revenues of $1,390,623 and a loss of $(670,911), or $(0.03) per share, for its third fiscal quarter, compared to $25,819, resulting in a loss of $(1,519,829), or $(0.09) per share prior year. Natrol, Inc. Announces First Quarter Results Company reports net sales of $17.0 million compared to $17.7 million in the same period a year ago, while the net income was $73,000, compared to a loss of $592,000 in the prior year. Natrol, Inc. Announces First Quarter Results Company reports net sales of $17.0 million compared to $17.7 million in the same period a year ago, while the net income was $73,000, compared to a loss of $592,000 in the prior year. Lifeway Foods Reports Record 1st Quarter 2006 Results Company reports sales of $6,003,023 compared to $4,656,860 during the same period a year ago with operating income of $1,406,372 in the first quarter 2006, compared to $923,724 during the same period a year ago. Lifeway Foods Reports Record 1st Quarter 2006 Results Company reports sales of $6,003,023 compared to $4,656,860 during the same period a year ago with operating income of $1,406,372 in the first quarter 2006, compared to $923,724 during the same period a year ago. AMS Health Sciences, Inc. Announces First Quarter 2006 Financial Results Company reports net sales of $2,351,713 compared to $4,050,758 prior year, with a profit from continuing operations of $19,401 for the quarter, versus loss of $1,314,605 for the same period in 2005. AMS Health Sciences, Inc. Announces First Quarter 2006 Financial Results Company reports net sales of $2,351,713 compared to $4,050,758 prior year, with a profit from continuing operations of $19,401 for the quarter, versus loss of $1,314,605 for the same period in 2005. PacificHealth Laboratories Reports First Quarter Results Company reports revenues of $1,575,396 for the quarter ended March 31, 2006 compared to revenues of $997,661 for the same period in 2005, with net income of $2,619,293, or $0.22 per share fully diluted, versus a net loss attributable to common stockholders of ($724,679), or ($0.07) per share, for the same period in 2005. PacificHealth Laboratories Reports First Quarter Results Company reports revenues of $1,575,396 for the quarter ended March 31, 2006 compared to revenues of $997,661 for the same period in 2005, with net income of $2,619,293, or $0.22 per share fully diluted, versus a net loss attributable to common stockholders of ($724,679), or ($0.07) per share, for the same period in 2005. Allergy Research Group, Inc. Reports First Quarter Results Company reports revenues of $4,265,527 for the quarter compared to $4,111,173 for the same period last year, with net income of $325,683 compared to $319,533 prior year. Allergy Research Group, Inc. Reports First Quarter Results Company reports revenues of $4,265,527 for the quarter compared to $4,111,173 for the same period last year, with net income of $325,683 compared to $319,533 prior year. Nutrition 21 Reports Results For The Third Quarter Of Fiscal 2006 Company reports revenues of $2.5 million compared to $2.4 million for the same period last year, with a net loss of $2.3 million, or ($0.06) per diluted share, compared to a net loss of $1.9 million, or ($0.05) per diluted share, in the third quarter of fiscal 2005. Nutrition 21 Reports Results For The Third Quarter Of Fiscal 2006 Company reports revenues of $2.5 million compared to $2.4 million for the same period last year, with a net loss of $2.3 million, or ($0.06) per diluted share, compared to a net loss of $1.9 million, or ($0.05) per diluted share, in the third quarter of fiscal 2005. Forbes Medi-Tech announces Financial Results for the Quarter ended March 31, 2006 Company reports total revenue of $0.9 million for the quarter versus $1.0 million for same period last year, with net income of $0.09 per share for the quarter compared to a net loss per share of $0.07 for same period last year. Forbes Medi-Tech announces Financial Results for the Quarter ended March 31, 2006 Company reports total revenue of $0.9 million for the quarter versus $1.0 million for same period last year, with net income of $0.09 per share for the quarter compared to a net loss per share of $0.07 for same period last year. NutraCea Reports First Quarter Financial Results Company reports total revenues of $3,781,543, compared to total revenues of $459,314 for the first quarter of 2005, with a net loss of $233,570 or $(0.00) per share, compared to a net loss of $864,693, or $(0.02) per share in 2005. NutraCea Reports First Quarter Financial Results Company reports total revenues of $3,781,543, compared to total revenues of $459,314 for the first quarter of 2005, with a net loss of $233,570 or $(0.00) per share, compared to a net loss of $864,693, or $(0.02) per share in 2005. Vital Living Inc. Announces First Quarter Results Company reports revenue of $1.33 million compared to $1.26 million, and a net loss available to common stockholders of $187,000, or $0.0 basic and diluted loss per share, compared with $722,000, or $0.01 basic and diluted loss per share prior year. Vital Living Inc. Announces First Quarter Results Company reports revenue of $1.33 million compared to $1.26 million, and a net loss available to common stockholders of $187,000, or $0.0 basic and diluted loss per share, compared with $722,000, or $0.01 basic and diluted loss per share prior year. Natrol Secures Exclusive North American Rights for New Form of Stabilized NADH Company has entered into an exclusive patent licensing agreement with Oekopharm GmbH of Austria for the manufacture, sales, distribution and marketing of nicotinamide adenine dinucleotide hydride (NADH) in North America. Natrol Secures Exclusive North American Rights for New Form of Stabilized NADH Company has entered into an exclusive patent licensing agreement with Oekopharm GmbH of Austria for the manufacture, sales, distribution and marketing of nicotinamide adenine dinucleotide hydride (NADH) in North America. Natrol Secures Exclusive North American Rights for New Form of Stabilized NADH Company has entered into an exclusive patent licensing agreement with Oekopharm GmbH of Austria for the manufacture, sales, distribution and marketing of nicotinamide adenine dinucleotide hydride (NADH) in North America. Natrol Secures Exclusive North American Rights for New Form of Stabilized NADH Company has entered into an exclusive patent licensing agreement with Oekopharm GmbH of Austria for the manufacture, sales, distribution and marketing of nicotinamide adenine dinucleotide hydride (NADH) in North America. Natrol Secures Exclusive North American Rights for New Form of Stabilized NADH Company has entered into an exclusive patent licensing agreement with Oekopharm GmbH of Austria for the manufacture, sales, distribution and marketing of nicotinamide adenine dinucleotide hydride (NADH) in North America. Natrol Secures Exclusive North American Rights for New Form of Stabilized NADH Company has entered into an exclusive patent licensing agreement with Oekopharm GmbH of Austria for the manufacture, sales, distribution and marketing of nicotinamide adenine dinucleotide hydride (NADH) in North America. Natrol Secures Exclusive North American Rights for New Form of Stabilized NADH Company has entered into an exclusive patent licensing agreement with Oekopharm GmbH of Austria for the manufacture, sales, distribution and marketing of nicotinamide adenine dinucleotide hydride (NADH) in North America. Natrol Secures Exclusive North American Rights for New Form of Stabilized NADH Company has entered into an exclusive patent licensing agreement with Oekopharm GmbH of Austria for the manufacture, sales, distribution and marketing of nicotinamide adenine dinucleotide hydride (NADH) in North America. Natrol Secures Exclusive North American Rights for New Form of Stabilized NADH Company has entered into an exclusive patent licensing agreement with Oekopharm GmbH of Austria for the manufacture, sales, distribution and marketing of nicotinamide adenine dinucleotide hydride (NADH) in North America. Frutarom Reports First Quarter Results Company reports sales of $ 71.0 million, up 9.7% compared with the same quarter of 2005 with gross profit of US$ 27.0 million, compared with US$ 25.0 million in the same quarter of 2005. Frutarom Reports First Quarter Results Company reports sales of $ 71.0 million, up 9.7% compared with the same quarter of 2005 with gross profit of US$ 27.0 million, compared with US$ 25.0 million in the same quarter of 2005. Natrol, Inc. Establishes Subsidiary in the United Kingdom Company announces the establishment of a United Kingdom subsidiary, Natrol UK Ltd, with Margaret Peet to lead the overall operations of Natrol UK Ltd. Natrol, Inc. Establishes Subsidiary in the United Kingdom Company announces the establishment of a United Kingdom subsidiary, Natrol UK Ltd, with Margaret Peet to lead the overall operations of Natrol UK Ltd. Natrol, Inc. Establishes Subsidiary in the United Kingdom Company announces the establishment of a United Kingdom subsidiary, Natrol UK Ltd, with Margaret Peet to lead the overall operations of Natrol UK Ltd. Natrol, Inc. Establishes Subsidiary in the United Kingdom Company announces the establishment of a United Kingdom subsidiary, Natrol UK Ltd, with Margaret Peet to lead the overall operations of Natrol UK Ltd. Natrol, Inc. Establishes Subsidiary in the United Kingdom Company announces the establishment of a United Kingdom subsidiary, Natrol UK Ltd, with Margaret Peet to lead the overall operations of Natrol UK Ltd. Natrol, Inc. Establishes Subsidiary in the United Kingdom Company announces the establishment of a United Kingdom subsidiary, Natrol UK Ltd, with Margaret Peet to lead the overall operations of Natrol UK Ltd. Natrol, Inc. Establishes Subsidiary in the United Kingdom Company announces the establishment of a United Kingdom subsidiary, Natrol UK Ltd, with Margaret Peet to lead the overall operations of Natrol UK Ltd. Cognis to Start Global Cooperation With WILD Cognis and Wild have formed separate agreements for Europe and the United States for food applications under which Cognis ingredients will be incorporated into WILD’s flavor systems and fruit preparations, and the companies will jointly develop new products and systems and will work closely together in the field of marketing and sales. Cognis to Start Global Cooperation With WILD Cognis and Wild have formed separate agreements for Europe and the United States for food applications under which Cognis ingredients will be incorporated into WILD’s flavor systems and fruit preparations, and the companies will jointly develop new products and systems and will work closely together in the field of marketing and sales. Cognis to Start Global Cooperation With WILD Cognis and Wild have formed separate agreements for Europe and the United States for food applications under which Cognis ingredients will be incorporated into WILD’s flavor systems and fruit preparations, and the companies will jointly develop new products and systems and will work closely together in the field of marketing and sales. Cognis to Start Global Cooperation With WILD Cognis and Wild have formed separate agreements for Europe and the United States for food applications under which Cognis ingredients will be incorporated into WILD’s flavor systems and fruit preparations, and the companies will jointly develop new products and systems and will work closely together in the field of marketing and sales. Cognis to Start Global Cooperation With WILD Cognis and Wild have formed separate agreements for Europe and the United States for food applications under which Cognis ingredients will be incorporated into WILD’s flavor systems and fruit preparations, and the companies will jointly develop new products and systems and will work closely together in the field of marketing and sales. Valensa Appoints Dr. Rudi E. Moerck President Company has appointed Dr. Rudi E. Moerck as President to also lead both the technology development and new product commercialization efforts for the company. Valensa Appoints Dr. Rudi E. Moerck President Company has appointed Dr. Rudi E. Moerck as President to also lead both the technology development and new product commercialization efforts for the company. Valensa Appoints Dr. Rudi E. Moerck President Company has appointed Dr. Rudi E. Moerck as President to also lead both the technology development and new product commercialization efforts for the company. Valensa Appoints Dr. Rudi E. Moerck President Company has appointed Dr. Rudi E. Moerck as President to also lead both the technology development and new product commercialization efforts for the company. Phosphagenics Announces Plans to Expand its Manufacturing Capabilities Company announces that it has commenced the building of a production plant in Melbourne which will permit a material increase in the Company's ability to manufacture tocopheryl phosphates, vital components of many of its pharmaceutical and nutraceutical products. The new facility is expected to be ready by the end of 2006. Phosphagenics Announces Plans to Expand its Manufacturing Capabilities Company announces that it has commenced the building of a production plant in Melbourne which will permit a material increase in the Company's ability to manufacture tocopheryl phosphates, vital components of many of its pharmaceutical and nutraceutical products. The new facility is expected to be ready by the end of 2006. Hansen Natural Signs Mexican Distribution Agreement Company has signed a distribution agreement with Cadbury Bebidas, S.A. de C.V. for distribution of Monster Energy drinks in Mexico. Hansen Natural Signs Mexican Distribution Agreement Company has signed a distribution agreement with Cadbury Bebidas, S.A. de C.V. for distribution of Monster Energy drinks in Mexico. Tate & Lyle PLC Announces Filing of Suit Alleging Infringement of Patented Sucralose Manufacturing Technology Company filed suit yesterday in the US District Federal Court for Central Illinois against a Chinese manufacturing group based in Hebei province, as well as six importers of sucralose into the US, alleging infringement of patented sucralose manufacturing technology in respect of sucralose manufactured in China. Tate & Lyle PLC Announces Filing of Suit Alleging Infringement of Patented Sucralose Manufacturing Technology Company filed suit yesterday in the US District Federal Court for Central Illinois against a Chinese manufacturing group based in Hebei province, as well as six importers of sucralose into the US, alleging infringement of patented sucralose manufacturing technology in respect of sucralose manufactured in China. Tim Welch Resigns from Alacer Corp. Tim Welch has resigned as president of Alacer, effective immediately with Ron Fugate assuming the duties of acting president in addition to his role as the company's chief operating officer. Tim Welch Resigns from Alacer Corp. Tim Welch has resigned as president of Alacer, effective immediately with Ron Fugate assuming the duties of acting president in addition to his role as the company's chief operating officer. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Another Reason to Choose Healthy Lifestyle Habits Another Reason to Choose Healthy Lifestyle Habits	Lonza Group announces the acquisition of assets which comprise Larex, Inc.’s Larch Arabinogalactan business. This strategic acquisition includes among other things, intellectual property, proprietary processing technology, manufacturing operations in Cohasset, Minnesota (USA), certain inventory and customer lists. Larex, Inc. is the exclusive North American vertically integrated manufacturer of the nutritional compound Larch Arabinogalactan (“LAG”), a natural soluble fiber extracted from harvested Larch trees. LAG is extracted and purified through a patented and proprietary process to deliver functionally optimized products sold into the health science, consumer and industrial markets. LAG, a natural, bioactive compound for use in human and animal nutrition, personal care and industrial applications, is generally recognized as safe (GRAS). It has been found to offer many significant benefits, the most important ones being in the fields of immune enhancement and digestive health. LAG products provide multifunctional properties either in stand-alone products or when combined with other ingredients to enhance product performance. With the acquisition of Larch Arabinogalactan, Lonza further expands its portfolio of nutrition businesses within Organic Fine & Performance Chemicals. This Lonza division thus continues to actively broaden its innovative offerings and complements the existing product line. About Lonza Lonza, a chemical and biotechnology company driven by the life sciences, generated sales of CHF 2.52 billion in 2005. Headquartered in Switzerland, Lonza operates 22 production and R&D sites around the world. Its 6300 employees are passionately committed to delivering sustainable value to their customers. Lonza is one of the leading custom manufacturers of chemical intermediates, active ingredients and biopharmaceuticals for the pharmaceutical and agrochemical industries. On the basis of organic and performance chemicals and biotechnology platforms, Lonza creates value-added solutions for the nutrition, hygiene & personal care, wood & water treatment and industrial specialty markets. Lonza also offers polymer intermediates, resins and compounds. Lonza is listed on the SWX Swiss Exchange. Further information can be found on our website www.lonza.com.
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software